Investing.com
Published Jul 15, 2025 07:51AM ET
Investing.com - Cantor Fitzgerald has maintained its Overweight rating and $11.00 price target on MiMedx Group (NASDAQ:MDXG) following a significant Medicare reimbursement policy proposal. According to InvestingPro data, the company maintains strong financials with an 82% gross margin and positive earnings of $0.27 per share over the last twelve months.
The firm's decision comes after the Centers for Medicare & Medicaid Services (CMS) released its Calendar Year 2026 Medicare Physician Fee Schedule Proposed Rule.
The proposed rule outlines what Cantor Fitzgerald describes as "a fundamental shift in how skin substitute products are reimbursed" under Medicare.
MiMedx Group specializes in placental tissue products used for wound care and surgical applications, making Medicare reimbursement policies particularly relevant to its business model.
The maintained Overweight rating suggests Cantor Fitzgerald remains positive on MiMedx's outlook despite the pending reimbursement structure changes that will take effect in 2026.
In other recent news, MiMedx Group Inc . reported its first-quarter earnings for 2025, meeting analyst expectations with an earnings per share (EPS) of $0.06 and surpassing revenue forecasts with $88.2 million. The company achieved a 4% year-over-year growth in net sales, driven by a 16% increase in surgical sales, although wound sales declined by 2%. Despite these positive financial results, MiMedx faces ongoing challenges with Medicare reimbursement policies. The Centers for Medicare & Medicaid Services (CMS) proposed significant changes to the reimbursement of skin substitutes, which could impact companies like MiMedx. CMS's proposal aims to eliminate product-specific reimbursement, potentially reducing spending on these products by nearly 90%. Analyst Ryan Zimmerman from BTIG noted that while the proposal appears severe, it might lead to market consolidation. Despite the proposal's impact, Zimmerman maintains a buy rating on Organogenesis. MiMedx's CEO, Joe Capper, emphasized the company's commitment to advocating for market reform and expressed confidence in future growth prospects, projecting high single-digit revenue growth for the full year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.